scholarly journals Immunotherapy with Canarypox Vaccine and Interleukin-2 for HIV-1 Infection: Termination of a Randomized Trial

2007 ◽  
Vol 2 (1) ◽  
pp. e5 ◽  
Author(s):  
Kendall A Smith ◽  
Sofija Andjelic ◽  
Zoran Popmihajlov ◽  
Liza Kelly-Rossini ◽  
Aquanette Sass ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Interleukin 2 ◽  
Hiv 1

scholarly journals A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients

AIDS ◽  
2009 ◽  
Vol 23 (3) ◽  
pp. 357-368 ◽  
Author(s):  
Lisa M Demeter ◽  
Hongyu Jiang ◽  
A Lisa Mukherjee ◽  
Gene D Morse ◽  
Robin DiFrancesco ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Randomized Trial ◽  
Protease Inhibitors ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Hiv 1

scholarly journals Simplification Therapy with Once‐Daily Emtricitabine, Didanosine, and Efavirenz in HIV‐1–Infected Adults with Viral Suppression Receiving a Protease Inhibitor–Based Regimen: A Randomized Trial

2005 ◽  
Vol 191 (6) ◽  
pp. 830-839 ◽  
Author(s):  
Jean‐Michel Molina ◽  
Valérie Journot ◽  
Laurence Morand‐Joubert ◽  
Patrick Yéni ◽  
Willy Rozenbaum ◽  
...  
Keyword(s):  
Protease Inhibitor ◽  
Randomized Trial ◽  
Viral Suppression ◽  
Once Daily ◽  
Hiv 1

scholarly journals Plasma Biomarkers to Detect Prevalent or Predict Progressive Tuberculosis Associated With Human Immunodeficiency Virus–1

2018 ◽  
Vol 69 (2) ◽  
pp. 295-305 ◽  
Author(s):  
Maia Lesosky ◽  
Molebogeng X Rangaka ◽  
Cara Pienaar ◽  
Anna K Coussens ◽  
Rene Goliath ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Transforming Growth Factor ◽  
Controlled Trial ◽  
Interleukin 2 ◽  
Diagnostic Tools ◽  
Control Group ◽  
Plasma Biomarkers ◽  
Network Analyses ◽  
Immunodeficiency Virus ◽  
Hiv 1

Abstract Background The risk of individuals infected with human immunodeficiency virus (HIV)-1 developing tuberculosis (TB) is high, while both prognostic and diagnostic tools remain insensitive. The potential for plasma biomarkers to predict which HIV-1–infected individuals are likely to progress to active disease is unknown. Methods Thirteen analytes were measured from QuantiFERON Gold in-tube (QFT) plasma samples in 421 HIV-1–infected persons recruited within the screening and enrollment phases of a randomized, controlled trial of isoniazid preventive therapy. Blood for QFT was obtained pre-randomization. Individuals were classified into prevalent TB, incident TB, and control groups. Comparisons between groups, supervised learning methods, and weighted correlation network analyses were applied utilizing the unstimulated and background-corrected plasma analyte concentrations. Results Unstimulated samples showed higher analyte concentrations in the prevalent and incident TB groups compared to the control group. The largest differences were seen for C-X-C motif chemokine 10 (CXCL10), interleukin-2 (IL-2), IL-1α, transforming growth factor-α (TGF-α). A predictive model analysis using unstimulated analytes discriminated best between the control and prevalent TB groups (area under the curve [AUC] = 0.9), reasonably well between the incident and prevalent TB groups (AUC > 0.8), and poorly between the control and incident TB groups. Unstimulated IL-2 and IFN-γ were ranked at or near the top for all comparisons, except the comparison between the control vs incident TB groups. Models using background-adjusted values performed poorly. Conclusions Single plasma biomarkers are unlikely to distinguish between disease states in HIV-1 co-infected individuals, and combinations of biomarkers are required. The ability to detect prevalent TB is potentially important, as no blood test hitherto has been suggested as having the utility to detect prevalent TB amongst HIV-1 co-infected persons.

scholarly journals Induction of TAK (Cyclin T1/P-TEFb) in Purified Resting CD4+ T Lymphocytes by Combination of Cytokines

2001 ◽  
Vol 75 (23) ◽  
pp. 11336-11343 ◽  
Author(s):  
Romi Ghose ◽  
Li-Ying Liou ◽  
Christine H. Herrmann ◽  
Andrew P. Rice
Keyword(s):  
T Lymphocytes ◽  
Rna Polymerase Ii ◽  
Interleukin 2 ◽  
Cellular Protein ◽  
Peripheral Blood Lymphocytes ◽  
Tat Protein ◽  
Necrosis Factor Alpha ◽  
Cyclin T1 ◽  
Protein Levels ◽  
Hiv 1

ABSTRACT Combinations of cytokines are known to reactivate transcription and replication of latent human immunodeficiency virus type 1 (HIV-1) proviruses in resting CD4+ T lymphocytes isolated from infected individuals. Transcription of the HIV-1 provirus by RNA polymerase II is strongly stimulated by the viral Tat protein. Tat function is mediated by a cellular protein kinase known as TAK (cyclin T1/P-TEFb) that is composed of Cdk9 and cyclin T1. We have found that treatment of peripheral blood lymphocytes and purified resting CD4+ T lymphocytes with the combination of interleukin-2 (IL-2), IL-6, and tumor necrosis factor alpha resulted in an increase in Cdk9 and cyclin T1 protein levels and an increase in TAK enzymatic activity. The cytokine induction of TAK in resting CD4+ T lymphocytes did not appear to require proliferation of lymphocytes. These results suggest that induction of TAK by cytokines secreted in the microenvironment of lymphoid tissue may be involved in the reactivation of HIV-1 in CD4+ T lymphocytes harboring a latent provirus.

Chemokine receptor genotype and response to interleukin-2 therapy in HIV-1-infected individuals

2003 ◽  
Vol 106 (1) ◽  
pp. 36-40 ◽  
Author(s):  
Alison Clegg ◽  
Peter Williamson ◽  
Robyn Biti ◽  
David Cooper ◽  
Sean Emery ◽  
...  
Keyword(s):  
Chemokine Receptor ◽  
Interleukin 2 ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document